Fosamax Trial Expert Stumbles Over Report Origins

Law360, New York (June 15, 2010, 6:23 PM EDT) -- A health sciences researcher admitted in court that a U.S. Food and Drug Administration report critical of Merck & Co. osteoperosis drug Fosamax had not received an official sign-off by the agency, calling into question evidence used by plaintiff Shirley Boles in a bellwether case over alleged health risks associated with the drug.

Wake Forest University School of Medicine professor Curt Furberg, who testified on behalf of Boles in the U.S. District Court for the Southern District of New York, acknowledged that a medical officer had...
To view the full article, register now.